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Ibrutinib repurposing: from B-cell malignancies to solid tumors
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Ibrutinib (Imbruvica®, also known as PCI-32765) 
is a first-in-class, irreversible small-molecule inhibitor 
of Bruton’s Tyrosine Kinase (BTK) that binds covalently 
to cysteine C481 within the ATP-binding pocket. Since 
BTK is a Tec family non-receptor tyrosine kinase that 
is specifically required for B-cell antigen receptor 
(BCR) signaling, ibrutinib was initially developed for 
the treatment of B-cell malignancies. Currently, it is 
approved for first-line treatment of chronic lymphocytic 
leukemia, and for the treatment of mantle-cell lymphoma 
and Waldenström’s macroglobulinemia patients that have 
received at least one previous therapy.
However, BTK is also involved in signaling pathways 
downstream of many other receptors and its expression 
is not restricted to B cells. In fact, it is expressed in all 
hematopoietic lineages with the exception of T lymphocytes. 
Taking advantage of this aspect of BTK biology, some 
groups, including ours, have exploited the utility of 
inhibiting BTK in different cell types other than B cells. In 
particular, we validated the critical role of BTK for mast cell 
degranulation in mouse models of pancreatic cancer, namely 
insulinoma [1] and pancreatic ductal adenocarcinoma 
(PDAC) [2]. Ibrutinib was effective in both scenarios, leading 
to vasculature collapse and tumor regression in insulinoma 
and to a potent and unexpected anti-fibrotic effect in PDAC, 
where it synergized with standard of care chemotherapy to 
extend mice survival. This latter observation suggests that 
the anti-fibrotic activity of ibrutinib could be beneficial 
also for the treatment of other fibrotic diseases, an aspect 
that deserves further studies. More recently, Gunderson and 
colleagues contributed to the understanding of ibrutinib 
therapeutic impact in PDAC by describing how BTK 
regulates B-cell and macrophage-mediated T-cell suppression 
and demonstrating that ibrutinib restores T-cell dependent 
anti-tumor responses and triggers growth inhibition [3]. 
These studies combined led to the initiation of a phase 2/3 
clinical trial for the use of ibrutinib in combination with nab-
paclitaxel and gemcitabine in metastatic PDAC.
Importantly, emerging data obtained from various 
mouse models of cancer suggests that beneficial use of 
ibrutinib could extend beyond pancreatic cancer to other 
solid tumors. For example, myeloid-derived suppressor 
cells (MDSCs) express BTK and are present in the stroma 
of many different tumors, causing immunosuppression and 
evasion of anti-tumor immune responses. Consistently, 
treatment of breast cancer and melanoma mouse models 
with ibrutinib reduced the number of MDSCs in the spleen 
and the tumor, and combination therapy with anti-PD-L1 
resulted in reduced mammary tumor growth [4]. Moreover, 
synergy of ibrutinib with immune checkpoint blockade has 
also been reported in mouse models of lymphoma, breast 
and colon cancer, but in a BTK-independent manner 
[5]. In this case, suppression of tumor growth was due 
to inhibition of the interleukin-2–inducible T-cell kinase 
(ITK), an enzyme required by Th2 T cells, allowing a 
shift of T-cell immune responses to a Th1 bias. However, 
off-target (BTK-independent) effects of ibrutinib are not 
limited to ITK, since its inhibitory activity affects several 
other kinases including Tec, EGFR, HER2, HER3, HER4, 
JAK3, Blk, Fgr, Hck, Lck, Yes/YES1, Bmx/Etk and Txk. 
While this lack of selectivity could explain some of its side 
effects, it could be exploited for the treatment of tumors 
without BTK dependency. Indeed, two recent reports 
exemplify this approach by showing promising in vitro 
data against EGFR-mutant or overexpressed non-small cell 
lung cancer (NSCLC) [6] and HER2-positive breast cancer.
Finally, expression of BTK variants was found in 
cancer cells of breast, prostate [7] and colon tumors [8]. 
In all cases, its downregulation by RNAi or its inhibition 
by pharmacological means, including ibrutinib, leads to 
impaired proliferation and/or cell death.
All these findings broaden the spectrum of tumor 
types potentially susceptible to treatment with ibrutinib. 
Its use against solid tumors, alone or in combination with 
standard therapies or novel immune-based approaches, 
is increasingly becoming a clinically viable option. 
Indeed, a number of clinical trials are already underway 
for the treatment of different solid tumor types, such as 
EGFR mutant NSCLC (ClinicalTrials.gov Identifier: 
NCT02321540), refractory stage IV cutaneous melanoma 
(NCT02581930), metastatic pancreatic adenocarcinoma 
(NCT02562898 and NCT02436668), localized prostate 
cancer (NCT02643667), advanced gastrointestinal and 
genitourinary tumors (NCT02599324), advanced carcinoid 
and pancreatic neuroendocrine tumors (NCT02575300) and 
other relapsed or refractory solid tumors including lung and 
breast (NCT02403271). Results of these trials will shed light 
on the applicability of ibrutinib in human patients beyond 
hematological malignancies and quickly open the way to 
new immediate clinical applications. Nevertheless, further 
work will be needed in order to establish, for every tumor 
type, the contribution of BTK-related responses versus 
inhibition of other kinases, either in tumor cells themselves 
or in the tumor stroma.
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Ibrutinib constitutes a prime example of therapeutic 
switching, but there are likely many other drugs already in 
clinical use that are candidates for repositioning, and could 
offer new, safe and easily-implementable opportunities for 
cancer patients.
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